Evaluation and Management of Anemia in Stage 4 CKD
This patient requires immediate iron studies (ferritin and transferrin saturation) to guide treatment, followed by intravenous iron supplementation as first-line therapy if iron deficiency is confirmed, before considering erythropoiesis-stimulating agents.
Initial Diagnostic Evaluation
The CBC shows mild normocytic anemia (Hb 11.2 g/dL, MCV 91.4 fL) with elevated RDW (16.3), which is consistent with anemia of CKD but requires further workup to identify treatable causes 1, 2.
Essential initial laboratory tests include:
- Serum ferritin level 1
- Transferrin saturation (TSAT) 1
- Absolute reticulocyte count 1
- Serum vitamin B12 and folate levels 1
The elevated RDW suggests mixed causes or evolving iron deficiency, making iron studies particularly critical 1.
Iron Status Assessment and Treatment Thresholds
Iron deficiency in CKD Stage 4 is defined as:
- Serum ferritin <100 ng/mL AND/OR
- TSAT <20% 1
Functional iron deficiency (inadequate iron delivery despite adequate stores) occurs when TSAT <20% even with ferritin 100-500 ng/mL, particularly common when erythropoiesis is stimulated 1.
Treatment Algorithm Based on Iron Studies:
If ferritin <100 ng/mL or TSAT <20%:
- Initiate intravenous iron therapy (oral iron is inadequate for CKD patients) 1
- Typical regimen: 200 mg IV weekly for 3 weeks, then reassess 1
- Target: ferritin >100 ng/mL and TSAT >20% 1
If ferritin 100-500 ng/mL with TSAT <30%:
- Consider trial of IV iron (50-125 mg weekly for 8-10 doses) 1
- Monitor response: rising hemoglobin indicates functional iron deficiency
- No response suggests inflammatory block 1
Erythropoiesis-Stimulating Agent Considerations
ESA therapy should be considered only after:
- Iron deficiency has been corrected (ferritin >100 ng/mL, TSAT >20%) 1
- Hemoglobin remains <10.0 g/dL despite adequate iron stores 1, 2
- Other causes of anemia have been excluded 1
Target hemoglobin range: 10-12 g/dL (avoid exceeding 12 g/dL due to cardiovascular risks) 1.
This patient's current Hb of 11.2 g/dL is actually within acceptable range, making ESA therapy premature until iron status is fully evaluated 1, 2.
Additional Causes to Exclude
Given the normocytic anemia with elevated RDW, evaluate for:
- Chronic inflammation (C-reactive protein, especially if ferritin elevated with low TSAT) 1
- Severe hyperparathyroidism (PTH level) 1
- Hypothyroidism (TSH) 1
- Occult blood loss (stool guaiac, especially with ongoing iron deficiency) 1
Monitoring Strategy
Once treatment initiated:
- Recheck CBC, ferritin, and TSAT in 2-3 months 1
- If on IV iron alone: assess response and need for maintenance dosing 1
- If ESA eventually required: monitor iron studies every 3 months minimum 1
Critical Pitfalls to Avoid
Do not start ESA therapy before correcting iron deficiency - this leads to poor response and unnecessarily high ESA doses 1.
Do not use oral iron in CKD Stage 4 - absorption is inadequate to meet erythropoietic demands, particularly if ESA therapy becomes necessary 1.
Do not ignore the elevated RDW - this suggests evolving deficiency or mixed pathology requiring thorough evaluation 1.
Avoid treating to hemoglobin >12 g/dL - higher targets increase cardiovascular risk without additional benefit 1, 2, 3.